NCT00699296终止2 期
A Phase II Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 7
- 主要终点
- Overall response (CR/PR) rate by using the modified Severity-Weighted Assessment Tool (mSWAT) to assess skin disease and the combined evaluation of disease in the viscera/lymph nodes, peripheral blood and bone marrow
研究概览
简要总结
This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma. LBH589 is administered orally once a day for three days per week.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: Panobinostat (LBH589) (Drug)
结局指标
主要结局
Overall response (CR/PR) rate by using the modified Severity-Weighted Assessment Tool (mSWAT) to assess skin disease and the combined evaluation of disease in the viscera/lymph nodes, peripheral blood and bone marrow
时间窗: Every Cycle
次要结局
- Response rate using mSWAT Response rate using the Physician's Global Assessment of Clinical Condition (PGA) Responses in index lesions by skin lesion measurements and with photographic supporting documentation Overall response(CR/PR) rate by using PG(1 cycle)
研究者
研究点 (7)
Loading locations...
相似试验
终止
2 期
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic PhaseChronic Myeloid Leukemia in Chronic PhaseNCT00451035Novartis Pharmaceuticals29
终止
2 期
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast PhaseLeukemia, Myeloid, ChronicNCT00449761Novartis Pharmaceuticals27
终止
2 期
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)Cutaneous T-Cell LymphomaNCT00490776Novartis Pharmaceuticals9
进行中（未招募）
不适用
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell LymphomaAdult patients with stages IB to IVA mycosis fungoides (MF) or Sézary syndrome (SS). Patients with any history of visceral involvement of their CTCL will not be eligible for this study. Patients with Sézary syndrome and bone marrow involvement are eligible. All patients must have received at least two prior systemic treatment regimens for their MF or SS.MedDRA version: 14.1Level: LLTClassification code 10011679Term: Cutaneous T-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-000880-27-ESovartis Farmacéutica, S.A.139
已完成
2 期
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell LymphomaCutaneous T-Cell LymphomaNCT00425555Novartis Pharmaceuticals139